The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Tue., Jul. 7, 5:51 PM

Slide #2. Atara Biotherapeutics, Inc. Secondary Offering

Company: Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Date announced: 7/7/2015
Secondary Offering Details: Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $125.0 million. In addition, Atara Bio expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. All of the shares in the offering will be sold by Atara Bio.

Atara Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with a focus on muscle wasting conditions and oncology. Co.'s products are biologics targeting myostatin and activin, members of the Transforming Growth Factor-Beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. Co.'s product, PINTA 745, is for protein-energy wasting, a condition affecting many end-stage renal disease patients. Co.'s second product is STM 434 for ovarian cancer and other solid tumors. Co. has five additional products in development.
Open the ATRA Page at The Online Investor »

Company Name:  Atara Biotherapeutics Inc
Website:  www.atarabio.com
Sector:  Biotechnology
Number of ETFs Holding ATRA:  12
Total Market Value Held by ETFs:  $13.50M
Total Market Capitalization:  $1.11B
% of Market Cap. Held by ETFs:  1.22%
 

Open the ATRA Page at The Online Investor (in a new window) »

July 7, 2015    5:51 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
91st percentile
(ranked higher than approx. 91% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.